Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Follicular | 1 | 2018 | 13 | 0.590 |
Why?
|
| Antibodies | 1 | 2018 | 124 | 0.560 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 318 | 0.510 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2014 | 3 | 0.470 |
Why?
|
| Polyethylene | 1 | 2014 | 12 | 0.470 |
Why?
|
| Cryoprotective Agents | 1 | 2014 | 4 | 0.470 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2014 | 8 | 0.470 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2014 | 11 | 0.470 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 42 | 0.460 |
Why?
|
| Anus Neoplasms | 1 | 2014 | 4 | 0.450 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 38 | 0.450 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 93 | 0.440 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 112 | 0.420 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 342 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 312 | 0.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 375 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2022 | 69 | 0.330 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2022 | 7 | 0.200 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2023 | 216 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 27 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 28 | 0.200 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2023 | 94 | 0.200 |
Why?
|
| Thrombosis | 1 | 2023 | 147 | 0.190 |
Why?
|
| Humans | 11 | 2023 | 27160 | 0.180 |
Why?
|
| Adult | 6 | 2023 | 7506 | 0.170 |
Why?
|
| Male | 6 | 2023 | 13040 | 0.170 |
Why?
|
| Intracranial Embolism | 1 | 2019 | 6 | 0.160 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 134 | 0.150 |
Why?
|
| Female | 7 | 2023 | 14661 | 0.150 |
Why?
|
| Lymphoma | 1 | 2017 | 22 | 0.150 |
Why?
|
| Stroke | 1 | 2019 | 241 | 0.130 |
Why?
|
| Agglutination Tests | 1 | 2014 | 8 | 0.120 |
Why?
|
| Alemtuzumab | 1 | 2014 | 4 | 0.120 |
Why?
|
| Levonorgestrel | 1 | 2014 | 5 | 0.120 |
Why?
|
| Polycythemia Vera | 1 | 2014 | 14 | 0.120 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2014 | 1 | 0.120 |
Why?
|
| Quinazolines | 1 | 2014 | 31 | 0.120 |
Why?
|
| Mice, SCID | 1 | 2014 | 59 | 0.120 |
Why?
|
| Mice, Inbred NOD | 1 | 2014 | 49 | 0.120 |
Why?
|
| Cryopreservation | 1 | 2014 | 12 | 0.120 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 42 | 0.120 |
Why?
|
| Janus Kinase 2 | 1 | 2014 | 36 | 0.120 |
Why?
|
| Device Removal | 1 | 2014 | 30 | 0.120 |
Why?
|
| Splenectomy | 1 | 2014 | 43 | 0.120 |
Why?
|
| Drug Resistance | 1 | 2014 | 42 | 0.110 |
Why?
|
| Ifosfamide | 1 | 2014 | 9 | 0.110 |
Why?
|
| Mitomycin | 1 | 2014 | 19 | 0.110 |
Why?
|
| Cetuximab | 1 | 2014 | 20 | 0.110 |
Why?
|
| Bone Marrow Cells | 1 | 2014 | 80 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2014 | 73 | 0.110 |
Why?
|
| Plasma Exchange | 1 | 2014 | 103 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 291 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 133 | 0.110 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 142 | 0.110 |
Why?
|
| Cisplatin | 1 | 2014 | 175 | 0.100 |
Why?
|
| Middle Aged | 4 | 2023 | 6913 | 0.100 |
Why?
|
| Paclitaxel | 1 | 2014 | 184 | 0.100 |
Why?
|
| Animals | 2 | 2018 | 10093 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 155 | 0.100 |
Why?
|
| Adolescent | 3 | 2023 | 2993 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 660 | 0.080 |
Why?
|
| Mice | 1 | 2014 | 4478 | 0.060 |
Why?
|
| Aged | 3 | 2023 | 5231 | 0.060 |
Why?
|
| Focus Groups | 1 | 2023 | 90 | 0.050 |
Why?
|
| SEER Program | 1 | 2023 | 46 | 0.050 |
Why?
|
| Graft Survival | 1 | 2022 | 27 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 64 | 0.050 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 101 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 14 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 27 | 0.050 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 15 | 0.050 |
Why?
|
| Outpatients | 1 | 2022 | 44 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 76 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 191 | 0.050 |
Why?
|
| Warfarin | 1 | 2019 | 94 | 0.040 |
Why?
|
| Autografts | 1 | 2017 | 3 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2023 | 1944 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 225 | 0.040 |
Why?
|
| Risk Factors | 1 | 2022 | 2038 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 411 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2022 | 2453 | 0.030 |
Why?
|
| Young Adult | 1 | 2023 | 2633 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2014 | 10 | 0.030 |
Why?
|
| Valine | 1 | 2014 | 12 | 0.030 |
Why?
|
| Phenylalanine | 1 | 2014 | 24 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 102 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 66 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2014 | 2286 | 0.020 |
Why?
|